Literature DB >> 18042173

CD8 cytotoxic T cells in cutaneous leishmaniasis.

J H Ruiz1, I Becker.   

Abstract

CD8 T cells are essential in the defence against viruses, yet little is known of their participation in the host defence against parasites, such as Leishmania, which can cause a variety of clinical diseases, such as localized cutaneous, diffuse cutaneous, mucocutaneous and visceral leishmaniasis. Murine models of leishmaniasis suggest that CD8 T cells participate through IFN-gamma production, yet their cytotoxic capacity also plays an important role, as has been found in patients infected with various Leishmania strains, where CD8 T cell cytotoxicity and apoptosis of autologous Leishmania-infected macrophages correlate with cure. Yet the mechanisms underlying the CD8 T activation in patients with leishmaniasis remain an enigma. It is possible that dendritic cells activate CD8 T cells through mechanisms that include antigen cross-presentation. Here we summarize the recent findings of CD8 T cells in cutaneous leishmaniasis and discuss their significance in the control of the disease. Further knowledge in this field will undoubtedly improve the design of therapeutic and vaccine strategies.

Entities:  

Mesh:

Year:  2007        PMID: 18042173     DOI: 10.1111/j.1365-3024.2007.00991.x

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  30 in total

Review 1.  Identifying vaccine targets for anti-leishmanial vaccine development.

Authors:  Shyam Sundar; Bhawana Singh
Journal:  Expert Rev Vaccines       Date:  2014-04       Impact factor: 5.217

2.  Ageing dangerously; homing of senescent CD8 T cells in cutaneous Leishmaniasis.

Authors:  Simon Milling
Journal:  Immunology       Date:  2020-04       Impact factor: 7.397

3.  Protective and pathological functions of CD8+ T cells in Leishmania braziliensis infection.

Authors:  Thiago Marconi Cardoso; Álvaro Machado; Diego Luiz Costa; Lucas P Carvalho; Adriano Queiroz; Paulo Machado; Phillip Scott; Edgar M Carvalho; Olívia Bacellar
Journal:  Infect Immun       Date:  2014-12-22       Impact factor: 3.441

4.  Case report: Transient success using prolonged treatment with miltefosine for a patient with diffuse cutaneous leishmaniasis infected with Leishmania mexicana mexicana.

Authors:  Alejandro Ordaz-Farias; Fania Z Muñoz-Garza; Farah K Sevilla-Gonzalez; Ana Arana-Guajardo; Jorge Ocampo-Candiani; Nancy Treviño-Garza; Ingeborg Becker; Adrian Camacho-Ortiz
Journal:  Am J Trop Med Hyg       Date:  2012-12-12       Impact factor: 2.345

5.  Immunological perspectives of leishmaniasis.

Authors:  Susanne Nylén; Shalini Gautam
Journal:  J Glob Infect Dis       Date:  2010-05

6.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

7.  CD8+ T cells as a source of IFN-γ production in human cutaneous leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Hossein Keshavarz; Rosita Edalat; Abdolfattah Sarrafnejad; Tahereh Shahrestani; Fereidoun Mahboudi; Ali Khamesipour
Journal:  PLoS Negl Trop Dis       Date:  2010-10-12

8.  Human immunodeficiency virus and leishmaniasis.

Authors:  Navid Ezra; Maria Teresa Ochoa; Noah Craft
Journal:  J Glob Infect Dis       Date:  2010-09

9.  Granzyme B Produced by Natural Killer Cells Enhances Inflammatory Response and Contributes to the Immunopathology of Cutaneous Leishmaniasis.

Authors:  Taís M Campos; Fernanda O Novais; Maíra Saldanha; Rúbia Costa; Morgana Lordelo; Daniela Celestino; Camilla Sampaio; Natália Tavares; Sérgio Arruda; Paulo Machado; Cláudia Brodskyn; Phillip Scott; Edgar M Carvalho; Lucas P Carvalho
Journal:  J Infect Dis       Date:  2020-03-02       Impact factor: 5.226

10.  CD8+ T cells in situ in different clinical forms of human cutaneous leishmaniasis.

Authors:  Marina Loyola Dantas; Juliana Cabral de Oliveira; Lucas Carvalho; Sara Timóteo Passos; Adriano Queiroz; Paulo Machado; Edgar Carvalho; Sérgio Arruda
Journal:  Rev Soc Bras Med Trop       Date:  2013 Nov-Dec       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.